The U.S. Food and Drug Administration (FDA) approved the use of ivacaftor (Kalydeco®) today for people ages 2 and older with cystic fibrosis who have at least one of the following five splice mutations: 3849+10kbC->T, 2789+5G->A, 3272-26A->G, 711+3A->G, E831X.
Patient and provider groups urge safeguard for the health and lives of millions of Americans with a bipartisan approach to reform.
|
2 min read
Ten patient and provider groups, representing millions of Americans, issued the following statement in response to the release of the nonpartisan Congressional Budget Office's (CBO) scores of two pieces of health care reform legislation currently being considered by the U.S. Senate.
|
2 min read
Patient and provider groups urge the Senate to work together in a bipartisan fashion to ensure that Americans have access to affordable health care.
|
2 min read
The organizations called on Congress to take a bipartisan approach to reform.
|
2 min read
New data show positive results in individuals with a single F508del mutation as well as people with two copies of F508del and support continued development of triple combination therapies.
|
6 min read
Today, the Senate released a new draft of the Better Care Reconciliation Act (BCRA), including an amendment that would allow insurance companies to offer plans not in compliance with critical patient protections in current law.
|
2 min read
Twelve patient/consumer groups urge senate to reject the bill.
|
2 min read
As part of the Cystic Fibrosis Foundation's ninth annual Teen Advocacy Day, 162 advocates from 38 states met with elected officials in Washington, D.C., to tell their stories and make sure the cystic fibrosis community is heard in ongoing health care reform discussions.
|
3 min read
Today, the U.S. Senate released its version of the health care reform bill, titled the Better Care Reconciliation Act, and in response, the Cystic Fibrosis Foundation affirmed its opposition to the legislation.
|
3 min read